Ipsen’s latest R&D alliance brings novel T cell-activating drugs for cancer
On the heels of reaching an acquisition agreement that brings Ipsen a commercialized follicular lymphoma drug, the Paris-based drugmaker is expanding its reach in cancer through a licensing deal that takes it into a new area of drug research. Ipsen is collaborating with Marengo Therapeutics, a startup with technology that activates T cells and gets … Read more